As the world’s largest exporter of generic drugs, India imports more than 70 per cent of the necessary ingredients from other countries. This arrangement came to a standstill due to the supply chain disruptions caused by the global pandemic. The turn of events drove India to ramp up production of pharmaceutical ingredients at short notice to meet global demand for drugs.
To improve productivity such that urgent demand can be met, many Indian pharma manufacturing operators are increasingly connecting operating technology (OT) with IT systems to make production as cost-efficient and adaptable as possible. While the convergence of OT and IT systems brings about many benefits, it also creates new avenues for cyberattacks to occur in once-isolated OT environments. A recent Forrester commissioned study revealed that 97 per cent of Indian organizations suffered one or more business-impacting cyberattacks and that 67 per cent of those involved OT systems.
According to a report, India-based pharmaceutical facilities are listed as among the world’s most vulnerable and are very likely to suffer a cyberattack. In the same report, nearly 45 per cent of the devices within Indian pharmaceutical facilities were targeted by cybercriminals in 2019 and this number is steadily growing. Therefore, to prevent future attacks in pharma manufacturing, it is essential to identify security gaps that could impact the integrity of operations.
Some of the gaps that can be leveraged by cybercriminals:
Continue reading your story on the app
Continue reading your story in the magazine
“We plan to launch our prevention and early detection service in India”
London headquartered Medix Global, a provider of innovative, high quality, medical management solutions, is gradually expanding its business in Asia. With its recent entry into India, the company is geared to provide access of its global healthcare services to Indian customers. It has strong credentials for providing customers with fast-tracked and personalized medical solutions, from the right diagnosis to optimized treatment pathways. BioSpectrum Asia spoke to Sigal Atzmon, Founder and CEO, Medix Global, London, UK to find out more about the company’s growth plans in Asia.
“We are planning to launch a new bioprocess controller in Q1 2021”
Bioprocess engineers develop and produce a multitude of products and ingredients available today. Their applications are diverse, and the products can be found in pharmaceutical, chemical, and nutrition industries. With an integrated portfolio comprising software, instruments, consumables, and services, Eppendorf can satisfy the demands of bioprocess development through production. To find out about what major is in store at Eppendorf Bioprocess, BioSpectrum spoke to Richard Mirro, Business Manager, Bioprocess at Eppendorf, Inc., US.
“We are confident that Sputnik V will be providing long-term immunization defence against potential new coronavirus infections”
On December 14, 2020, Moscow’s National Research Center for Epidemiology and Microbiology named ‘Gamaleya Center’ and the Russian Direct Investment Fund (RDIF) announced the efficacy of over 90 per cent of the Russian Sputnik V vaccine in Phase III post-registration clinical trials. RDIF joins partners and manufacturers in ramping up the production of Sputnik V. First batch of 300,000 doses of Sputnik V vaccine has already been delivered to Argentina by RDIF on December 24, 2020. In an interview with BioSpectrum Asia Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF), Russia shared more insight on the encouraging efficacy data of the Sputnik V with Biospectrum Asia.
“Australia has reinforced its standing as a world-class destination for early phase clinical development”
Avance Clinical, a leading Australian Contract Research Organization (CRO) for biotech firms, and winner of the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award, has recently partnered with Europe’s leading CRO, Cromos Pharma. The collaboration will allow biotech firms to quickly start their pre-IND early phase studies in Australia, thereafter, expanding to Central/Eastern Europe to access the large patient populations for their Phase II and III studies. In an email interaction with BioSpectrum, Yvonne Lungershausen, CEO, Avance Clinical, Australia spoke about the Australian CRO market, and the impact of COVID-19 crisis.
Evaluating COVID-19 vaccines on mutant viral strains
While the viral variants and vaccine trials are contesting with each other, Norway based Coalition for Epidemic Preparedness Innovations (CEPI) has launched a first-of-its-kind collaboration to tackle emergence of new COVID-19 viral strains and evaluate their impact on vaccine candidates in development. Tracking viral mutations and diversity is essential to ensure efficacy of COVID-19 vaccine candidates on mutant virulent strains.
Taiwan initiates new measures for management of medical masks
Taiwan has initiated two new measures to reinforce the management of medical masks.
HiMedia gets multiple nods for COVID-19 products
HiGenoMB, the molecular biology division of Indian firm HiMedia Laboratories has received the CE/IVD approval and a nod from the Indian Council of Medical Research (ICMR) for its COVID-19 range of products.
EuBiologics partners with IVI for COVID-19 vaccine development
The International Vaccine Institute (IVI) and South Korean company EuBiologics have exchanged a Memorandum of Understanding (MoU) to cooperate in the clinical development of the COVID-19 vaccine the company is currently developing.
2021 beckons MAJOR investments IN R&D
The life sciences industry in Asia Pacific (APAC) region entered the year 2020 with companies entering into new agreements for expansion and focusing on applied research to develop new drugs that are affordable. During 2020, the industry, which acted timely, as covered in the January 2020 issue of BioSpectrum Asia, witnessed unprecedented collaborations with the governments due to the unexpected spread of coronavirus since December 2019. COVID-19 is expected to remain a defining issue for the life sciences industry across the globe in 2021, compelling companies to invest heavily in research and development.
Singapore Gives Nod To Pfizer-BioNtech Covid-19 Vaccine
The Health Sciences Authority (HSA) has granted an authorization under the Pandemic Special Access Route (PSAR) for the Pfizer-BioNTech COVID-19 vaccine to be used in Singapore for the prevention of COVID-19.
Region To Region
Region To Region
YOGA & PEACE
DEEPAK CHOPRA speaks with DAAJI about the role Yoga has to play in bringing about world peace. This is an excerpt from their conversation broadcast on International Day of Peace, September 21, 2020. That documentary is available at https://heartfulness.org/en/international-day-of-peace/.
Create the habit of meditation
CHIRAG KULKARNI, Co-Founder and CMO of Medly Pharmacies in the USA, speaks with RISHIKA SHARMA about creating a regular meditation practice, so as to make it a habit. He also shares how meditation has benefited both his personal and professional life.
SHIA'S PRIVATE TEMPLE OF DOOM!
Indiana Jones gig derailed by abuse scandal
"Food Raconteur” Ashok Nageshwaran wants to tell you a story.
THE MAKING OF A MODEL MINORITY
Indian Americans rarely stop to ask why our entrance into American society has been so rapid—or to consider what we have in common with other nonwhite Americans.
Business at Its Best
With a big hand from the government, pharmaceutical companies delivered the vaccine that the world desperately needed. Here’s how something in 2020 went right for a change
In 2017, DR. VANDANA SHIVA spoke with KIM HUGHES about the sacredness of the Earth, the work she has been doing to bring awareness and change in the field of sustainable agriculture, and the importance of understanding our interconnectedness with Nature, and how we can change the way we eat.
DIAMONDS - A Luxury Gem Steeped in Fact & Fable
The diamond is one fabled gemstone! For example, google “Hope Diamond” to see all the legends associated with just this one stone said to bring misfortune to its owners.
Brown Sugaa and Medusa